JP2004131466A - フラビウイルス感染症の治療 - Google Patents

フラビウイルス感染症の治療 Download PDF

Info

Publication number
JP2004131466A
JP2004131466A JP2003158552A JP2003158552A JP2004131466A JP 2004131466 A JP2004131466 A JP 2004131466A JP 2003158552 A JP2003158552 A JP 2003158552A JP 2003158552 A JP2003158552 A JP 2003158552A JP 2004131466 A JP2004131466 A JP 2004131466A
Authority
JP
Japan
Prior art keywords
virus
flaviviridae
subject
ribavirin
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003158552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004131466A5 (https=
Inventor
Tsu-An Hsu
スーアン　スー
Yuan-Chin Tsai
ユェンジン　ツァイ
Der-Ren Hwang
ダーレン　ファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of JP2004131466A publication Critical patent/JP2004131466A/ja
Publication of JP2004131466A5 publication Critical patent/JP2004131466A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Packages (AREA)
JP2003158552A 2002-06-03 2003-06-03 フラビウイルス感染症の治療 Pending JP2004131466A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38503102P 2002-06-03 2002-06-03

Publications (2)

Publication Number Publication Date
JP2004131466A true JP2004131466A (ja) 2004-04-30
JP2004131466A5 JP2004131466A5 (https=) 2006-07-20

Family

ID=29550193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003158552A Pending JP2004131466A (ja) 2002-06-03 2003-06-03 フラビウイルス感染症の治療

Country Status (7)

Country Link
EP (1) EP1369120B1 (https=)
JP (1) JP2004131466A (https=)
KR (1) KR20030094097A (https=)
CN (1) CN1251687C (https=)
AT (1) ATE353658T1 (https=)
DE (1) DE60311702T2 (https=)
TW (1) TWI274585B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090058423A (ko) * 2007-12-04 2009-06-09 심형섭 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
TWI605822B (zh) * 2015-04-09 2017-11-21 高雄醫學大學 酪梨萃取物、ａｖｏｃａｄｅｎｏｌ Ｂ及（２Ｒ，４Ｒ）－１，２，４－三羥基十七碳－１６－炔的用途，以及包含酪梨萃取物之保健食品
EP3815699A1 (en) * 2019-10-28 2021-05-05 Technische Universität München New means and methods for therapy and diagnosis of adenoviral infection
IL295648A (en) * 2020-02-16 2022-10-01 Komipharm Int Australia Pty Ltd treatment method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0769903A (ja) * 1993-07-01 1995-03-14 Hatsuchiyou:Kk 抗ヒト免疫不全ウイルス剤およびエイズ治療薬
JPH08502030A (ja) * 1992-07-07 1996-03-05 コンキャノン，ピーター カラシ種子植物抽出物を含有する殺生物性組成物
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
WO2000062799A1 (en) * 1999-04-19 2000-10-26 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
WO2001049303A1 (en) * 2000-01-06 2001-07-12 Marantech Holding, Llc Multivalent electron active compositions and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011033A1 (en) * 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
JP4420997B2 (ja) * 1999-02-08 2010-02-24 利博 山瀬 抗ウィルス剤
JP2001233719A (ja) * 1999-12-13 2001-08-28 Natl Inst Of Advanced Industrial Science & Technology Meti 殺菌材および殺菌方法
US7744867B2 (en) * 2001-05-31 2010-06-29 The Cleveland Clinic Foundation PTPase inhibitors and method of using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502030A (ja) * 1992-07-07 1996-03-05 コンキャノン，ピーター カラシ種子植物抽出物を含有する殺生物性組成物
JPH0769903A (ja) * 1993-07-01 1995-03-14 Hatsuchiyou:Kk 抗ヒト免疫不全ウイルス剤およびエイズ治療薬
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
WO2000062799A1 (en) * 1999-04-19 2000-10-26 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
WO2001049303A1 (en) * 2000-01-06 2001-07-12 Marantech Holding, Llc Multivalent electron active compositions and methods of making and using same
WO2001049302A1 (en) * 2000-01-06 2001-07-12 Marantech Holding, Llc Compositions and methods for facilitating skin growth and managing skin conditions

Also Published As

Publication number Publication date
DE60311702D1 (de) 2007-03-29
DE60311702T2 (de) 2007-10-31
EP1369120A1 (en) 2003-12-10
CN1483413A (zh) 2004-03-24
CN1251687C (zh) 2006-04-19
TW200307558A (en) 2003-12-16
ATE353658T1 (de) 2007-03-15
KR20030094097A (ko) 2003-12-11
TWI274585B (en) 2007-03-01
EP1369120B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
JP5869469B2 (ja) 鉄が病因に関与する肝臓疾患の処置
JP5539363B2 (ja) インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
Cattral et al. Aplastic anemia after liver transplantation for fulminant liver failure
CN1984671A (zh) 环孢菌素和peg化干扰素的组合用于治疗丙型肝炎病毒(hcv)的用途
HUP0200942A2 (hu) Humán hepatitisz-C kezelése antioxidánsokkal társított ribavirint tartalmazó kombinációkkal
US20110270212A1 (en) Pharmacokinetic control for optimized interferon delivery
CN103096891A (zh) 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
WO2010031832A2 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
EP2214662B1 (en) (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
JP2004532840A (ja) 生体におけるエリトロポエチンによる化学療法誘発毒性の改善方法
MX2012004971A (es) Regimenes de dosificacion para terapia combinada del vhc, que comprende b1201335, interferon alfa y ribavirina.
Belani et al. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group
KR20230043598A (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염 및 항바이러스제를 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
JP2004131466A (ja) フラビウイルス感染症の治療
CN113304253A (zh) 一种辅助预防或辅助治疗新冠肺炎的食物及其应用
RU2417083C2 (ru) Применение активаторов растворимой гуанилатциклазы для лечения острых и хронических легочных заболеваний
JP3837769B2 (ja) 抗ウイルス剤
WO2008004653A1 (en) Prophylactic or therapeutic agent for viral disease
US20060024270A1 (en) Compositions and methods for preventing or treating encephalitis with interferon
Everson et al. Antiviral therapy for hepatitis C in the setting of liver transplantation
Giusto et al. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin
CN104284670B (zh) 用于治疗丙型病毒性肝炎的药剂
Boshra et al. Comparative Therapeutic Efficacy and Safety of Remdesivir monotherapy and its Combination of Lopinavir/Ritonavir in COVID-19 Patients
US20170049797A1 (en) Combination therapy for treating hcv infection
ES2969766T3 (es) Composiciones terapéuticas para tratar el cáncer de páncreas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101005